<DOC>
	<DOCNO>NCT01045564</DOCNO>
	<brief_summary>The purpose study characterize immunogenicity safety 3 dose GSK 's avian flu vaccine GSK 1557484A give different time interval adult age 18 year great increase occupational risk H5N1 exposure .</brief_summary>
	<brief_title>Safety Immunogenicity Vaccine Adults Occupational Risk Influenza A ( H5N1 ) Exposure</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female 18 year age great time first vaccination . At increase risk occupational exposure H5N1 influenza virus base : Exposure diseased poultry wild bird , Exposure , potential exposure , human case unidentified respiratory disease know avian influenza , Handling human avian microbiological specimen , Handling H5N1 viral isolates , Or status critical implementation emergency response measure event influenza pandemic declaration . Written inform consent obtain subject . Stable health status define absence health event satisfy definition serious adverse event , change ongoing drug therapy due therapeutic failure symptom drug toxicity , within one ( 1 ) month prior enrollment . Comprehension study requirement , ability comprehend comply procedure collection safety data , express availability require study period , ability willingness attend schedule visit . Presence evidence substance abuse neurological psychiatric diagnosis , although stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Presence oral temperature &gt; = 37.8ºC , acute symptom great `` mild '' severity schedule date first vaccination . Diagnosed cancer , treatment cancer , within 3 year . Persons history cancer diseasefree without treatment 3 year eligible . Persons history histologicallyconfirmed basal cell carcinoma skin successfully treat local excision except may enroll within 3 year diagnosis , histologic type skin cancer require 3 year untreated diseasefree window . Women diseasefree 3 year treatment breast cancer receive longterm prophylactic tamoxifen except may enroll . Any confirm suspected immunosuppressive immunodeficient condition include history human immunodeficiency virus ( HIV ) infection . Receipt systemic glucocorticoid within 1 month prior study enrollment , cytotoxic immunosuppressive drug within 6 month study enrollment . Receipt immunoglobulins and/or blood product within 3 month study enrollment plan administration product study period . Any significant disorder coagulation treatment warfarin derivative heparin . Persons receive individual dos low molecular weight heparin outside 24 hour prior vaccination , eligible . Persons receive prophylactic antiplatelet medication , e.g. , lowdose aspirin , without clinicallyapparent bleeding tendency , eligible . An acute evolve neurological disorder history GuillainBarré syndrome within 6 week receipt seasonal influenza vaccine . Administration vaccine within 30 day study vaccination . Exposure investigational nonregistered product ( drug vaccine ) trial , within 30 day prior study enrollment . Potential subject followup ( i.e. , treatment ) phase prior investigational study may enrol investigator 's judgment effect safety , reactogenicity , immunogenicity endpoint study ; violate protocol requirement prior trial . Any known suspected allergy constituent influenza vaccine ( include egg proteins mercurial preservative ) ; history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . Receipt analgesic antipyretic medication specific intent prophylaxis vaccine reactogenicity day treatment constitute contraindication administration study vaccine point time ; Known pregnancy positive urine betahuman chorionic gonadotropin ( βhCG ) test result prior vaccination . Lactating nursing . Women child bear potential lack history reliable contraceptive practice . The provision history NOT replace requirement perform , obtain negative result pregnancy urine test prior treatment . Reliable contraceptive practice include : consistent abstinence heterosexual activity , consistent use combine progestogen oral contraceptive , injectable progestogen , implant levonorgestrel , estrogen estrogen/ progestogen vaginal ring , percutaneous contraceptive patch intrauterine device ( IUD ) intrauterine system ( IUS ) , vasectomy document azoospermia &gt; = 6 month sole male partner , double barrier method ( condom occlusive cap plus spermicidal agent ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Vaccines</keyword>
	<keyword>H5N1</keyword>
	<keyword>Influenza</keyword>
	<keyword>Pandemic</keyword>
	<keyword>Human</keyword>
	<keyword>Avian</keyword>
	<keyword>Safety</keyword>
</DOC>